# Human ISG15 and USP18 Deficiencies Underlying Type I Interferonopathies

> **NIH NIH R01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $523,681

## Abstract

Project Summary
 Type I interferons (IFN-Is) have well-documented potent antiviral and inflammatory properties. However,
we and others have shown that the inflammatory effects of these cytokines can have detrimental effects on
human health. Disorders caused by the prolonged effects of IFN-Is are collectively known as type I
interferonopathies. Mendelian type I interferonopathies, such as Aicardi–Goutières syndrome (AGS) and
spondyloenchondromatosis (SPENCD) are prime examples of severe neurologic, autoinflammatory and
autoimmune diseases caused by the perpetual induction of IFN-Is.
 We have recently described more than 20 children presenting Mendelian type I interferonopathy.
Genetically, we have shown these conditions to be due to complete or partial deficiencies of ISG15 or USP18.
These deficiencies affect downregulation of the IFN-I response. Individuals with deficiencies of ISG15 or USP18
have high levels of IFN-I-stimulated gene products in their blood cells, high levels of resistance to viral infections,
but also neurologic, autoinflammatory and autoimmune manifestations, akin to those of AGS and SPENCD. This
proposal is built around the hypothesis that the pathogenesis of these deficiencies is driven by IFN-I responses
in specific tissues, and that these responses could be harnessed in the development of new treatments. We plan
to test this hypothesis by studying these deficiencies in vitro, ex vivo, and in vivo at the molecular, immunological,
and tissue-specific levels, to determine their functional significance in IFN-I pathway regulation and resistance
to viral infections in humans.
 Improvements in our understanding of the molecular regulation of IFN-I should shed light on the
pathophysiology of these deficiencies, paving the way for the development of new treatments for managing
persistent inflammatory disorders and enhancing antiviral responses.

## Key facts

- **NIH application ID:** 10453178
- **Project number:** 2R01AI127372-06
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Dusan Bogunovic
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $523,681
- **Award type:** 2
- **Project period:** 2017-06-09 → 2027-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10453178

## Citation

> US National Institutes of Health, RePORTER application 10453178, Human ISG15 and USP18 Deficiencies Underlying Type I Interferonopathies (2R01AI127372-06). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10453178. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*